Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

Abstract Background We assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI). Methods This was a post hoc individual patient-level meta-analysis of data from the Phase 3 studies M...

Full description

Bibliographic Details
Published in:Respiratory Research
Main Authors: Frank C. Albers, Alberto Papi, Camille Taillé, Daniel J. Bratton, Eric S. Bradford, Steven W. Yancey, Namhee Kwon
Format: Article
Language:English
Published: BMC 2019-07-01
Subjects:
Asthma
Asthma pharmacology
Body mass index
Body weight
Mepolizumab
Online Access:http://link.springer.com/article/10.1186/s12931-019-1134-7

Internet

http://link.springer.com/article/10.1186/s12931-019-1134-7

Similar Items